2 Covid-19 patients die of mucormycosis in Thane district; 6 hospitalised

Topics Coronavirus | corona | Thane

Two COVID-19 patients have died

due to mucormycosis, a serious but rare fungal infection, in Maharashtra's Thane district, a health official said on Wednesday.

Besides, six other patients are currently undergoing treatment for the disease, also known as black fungus, the official said.

A 38-year-old patient from Mharal in Thane rural and another one from Dombivli town died of the fungal infection while undergoing treatment at different COVID-19 care centres in Kalyan Dombivli Municipal Corporation (KDMC) limits, the civic body's health officer Dr Ashwini Patil said.

Six other patients were undergoing treatment for mucormycosis and two of them were admitted in the ICUs, she said.

The official also said COVID-19 patients need not panic as this fungal infection is mostly being found in those having diabetes. Such patients need to keep their blood sugar level under control, she said.

Mucormycosis is being detected in COVID-19 patients and there should not be an excessive use of steroids for their treatment, the official said.

According to health experts, the symptoms of mucormycosis include headache, fever, pain under the eyes, nasal or sinus congestion and partial loss of vision.

On Tuesday, Maharashtra Health Minister Rajesh Tope said there could be over 2,000 mucormycosis patients in the state as of now and with more and more COVID-19 cases coming up, "their number would increase for sure".

The state government has decided to use hospitals attached to medical colleges as treatment centres for mucormycosis, he had said.

Meanwhile, Lok Sabha member from Kalyan Dr Shrikant Shinde in a release said during a virtual meeting with Chief Minister Uddhav Thackeray over the weekend, he made several suggestions on how to tackle the fungal infection.

Shinde also suggested that a task force be set up to lay down protocols for the use of steroids for treating COVID-19 patients.


(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)


Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel